During the prescribed-use period:
After the prescribed-use period:
NIDA (NIH) has awarded us a grant to advance XpiRx through IND-enabling studies. We have identified our lead and backup candidates for upcoming non-clinical and clinical studies.
Our O2P opioids are designed to provide the following unprecedented features:
With the support of NIH/NIDA, we have demonstrated in vivo proof of concept for this program (see below), and have identified lead compounds for progression to non-clinical and clinical studies. Additional grants from NIH/NIDA and the State of Ohio (Ohio Third Frontier) supported the successful completion of IND-enabling studies and will support the human proof-of-concept study expected to be completed in 2021.